Immunotherapy in Prostate Cancer

被引：1

作者：

Bolat, Deniz ^{[1
,3
]}

Haydaroyu, Ayfer ^{[2
,3
]}

机构：

[1] Univ Hlth Sci, Izmir Bozyaka Training & Res Hosp, Clin Urol, Izmir, Turkey

[2] Ege Univ, Dept Radiat Oncol, Fac Med, Izmir, Turkey

[3] Ege Univ, Inst Hlth Sci, Dept Basic Oncol, Izmir, Turkey

来源：

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2019年 / 18卷 / 02期

关键词：

Prostate cancer; immunotherapy; vaccine; checkpoint blockers; survival; PHASE-III TRIAL; SIPULEUCEL-T; ANDROGEN DEPRIVATION; CTLA-4; BLOCKADE; DOSE-ESCALATION; PD-1; DOUBLE-BLIND; SURVIVAL; VACCINE; CHEMOTHERAPY;

D O I：

10.4274/uob.galenos.2018.1142

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, immunotherapy has become an important treatment alternative in the treatment of many cancers. Research on immunotherapy in prostate cancer has been accelerated by obtaining Food and Drug Administration (FDA) approval of sipuleucel-T for asymptomatic or minimal symptomatic metastatic castration-resistant prostate cancer (CRPC). Despite all these developments, the patients in whom these agents should be used, sequential use and combination strategies remain unclear. In this review, mechanisms of action and survival outcomes of different immunotherapeutic agents and therapeutic cancer vaccines in mCRPC are discussed.

引用

页码：67 / 72

页数：6

共 50 条

[1]

[Anonymous], 2017, J CLIN ONCOL S

[2]

[Anonymous], 2016, Ann Oncol, DOI [DOI 10.1093/ANNONC/MDW372.09, 10.1093/annonc/mdw372.09]

[3]

[Anonymous], ANN ONCOL

[4] Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway [J].

Ardiani, Andressa ;

Gameiro, Sofia R. ;

Kwilas, Anna R. ;

Donahue, Renee N. ;

Hodge, James W. .

ONCOTARGET, 2014, 5 (19) :9335-9348

[5] Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model [J].

Ardiani, Andressa ;

Farsaci, Benedetto ;

Rogers, Connie J. ;

Protter, Andy ;

Guo, Zhimin ;

King, Thomas H. ;

Apelian, David ;

Hodge, James W. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6205-6218

[6]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[7] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer [J].

Beer, Tomasz M. ;

Kwon, Eugene D. ;

Drake, Charles G. ;

Fizazi, Karim ;

Logothetis, Christopher ;

Gravis, Gwenaelle ;

Ganju, Vinod ;

Polikoff, Jonathan ;

Saad, Fred ;

Humanski, Piotr ;

Piulats, Josep M. ;

Gonzalez Mella, Pablo ;

Ng, Siobhan S. ;

Jaeger, Dirk ;

Parnis, Francis X. ;

Franke, Fabio A. ;

Puente, Javier ;

Carvajal, Roman ;

Sengelov, Lisa ;

McHenry, M. Brent ;

Varma, Arvind ;

van den Eertwegh, Alfonsus J. ;

Gerritsen, Winald .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :40-+

[8] PD-L1 is highly expressed in Enzalutamide resistant prostate cancer [J].

Bishop, Jennifer L. ;

Sio, Alexander ;

Angeles, Arkhjamil ;

Roberts, Morgan E. ;

Azad, Arun A. ;

Chi, Kim N. ;

Zoubeidi, Amina .

ONCOTARGET, 2015, 6 (01) :234-242

[9] Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). [J].

Boudadi, Karim ;

Suzman, Daniel L. ;

Luber, Brandon ;

Wang, Hao ;

Silberstein, John ;

Sullivan, Rana ;

Dowling, Donna ;

Harb, Rana ;

Nirschl, Thomas ;

Dittamore, Ryan Vance ;

Carducci, Michael Anthony ;

Eisenberger, Mario A. ;

Haffner, Michael ;

Meeker, Alan ;

Eshleman, James R. ;

Luo, Jun ;

Drake, Charles G. ;

Antonarakis, Emmanuel S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[10] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

← 1 2 3 4 5 →